S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Nevro Stock Forecast, Price & News

-1.76 (-1.44 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume337,922 shs
Average Volume487,485 shs
Market Capitalization$4.19 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

Nevro logo

About Nevro

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.09 out of 5 stars

Medical Sector

462nd out of 1,351 stocks

Surgical & Medical Instruments Industry

44th out of 123 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nevro (NYSE:NVRO) Frequently Asked Questions

Is Nevro a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nevro stock.
View analyst ratings for Nevro
or view top-rated stocks.

What stocks does MarketBeat like better than Nevro?

Wall Street analysts have given Nevro a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nevro wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nevro?

Nevro saw a decline in short interest during the month of August. As of August 13th, there was short interest totaling 2,500,000 shares, a decline of 28.6% from the July 29th total of 3,500,000 shares. Based on an average daily trading volume, of 538,500 shares, the days-to-cover ratio is presently 4.6 days. Currently, 7.3% of the shares of the company are sold short.
View Nevro's Short Interest

When is Nevro's next earnings date?

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Nevro

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) released its quarterly earnings data on Wednesday, August, 4th. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.09. The medical equipment provider earned $102.30 million during the quarter, compared to analyst estimates of $102.83 million. Nevro had a negative net margin of 16.68% and a negative trailing twelve-month return on equity of 18.29%. The company's revenue was up 81.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.21) earnings per share.
View Nevro's earnings history

How has Nevro's stock been impacted by Coronavirus?

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVRO stock has increased by 9.5% and is now trading at $120.20.
View which stocks have been most impacted by COVID-19

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its third quarter 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $90 million-$93 million, compared to the consensus revenue estimate of $115.35 million.

What price target have analysts set for NVRO?

14 analysts have issued 1-year price objectives for Nevro's stock. Their forecasts range from $112.00 to $205.00. On average, they anticipate Nevro's stock price to reach $147.82 in the next year. This suggests a possible upside of 23.0% from the stock's current price.
View analysts' price targets for Nevro
or view top-rated stocks among Wall Street analysts.

Who are Nevro's key executives?

Nevro's management team includes the following people:
  • D. Keith Grossman, Chairman, President & Chief Executive Officer
  • Patrick Schmitz, Vice President-Operations
  • Roderick H. MacLeod, Chief Financial Officer
  • David Caraway, Chief Medical Officer
  • Christopher Christoforou, Vice President-Technical Operations

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro CEO D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among Nevro's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), The Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (13.40%), Jefferies Group LLC (0.00%), BlackRock Inc. (11.38%), Vanguard Group Inc. (9.61%), Jackson Square Partners LLC (4.24%) and Invesco Ltd. (4.07%). Company insiders that own Nevro stock include Andrew H Galligan, D Keith Grossman, Doug Alleavitch, Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends for Nevro

Which major investors are selling Nevro stock?

NVRO stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BNP Paribas Arbitrage SA, Credit Suisse AG, Putnam Investments LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Bank of America Corp DE, and Marshall Wace North America L.P.. Company insiders that have sold Nevro company stock in the last year include Leslie Stretch, Michael F Demane, Niamh Louise Pellegrini, and Shawn Mccormick.
View insider buying and selling activity for Nevro
or view top insider-selling stocks.

Which major investors are buying Nevro stock?

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Jackson Square Partners LLC, BlackRock Inc., Principal Financial Group Inc., ArrowMark Colorado Holdings LLC, Bridger Management LLC, Massachusetts Financial Services Co. MA, and Redmile Group LLC.
View insider buying and selling activity for Nevro
or or view top insider-buying stocks.

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $120.20.

How much money does Nevro make?

Nevro has a market capitalization of $4.19 billion and generates $362.05 million in revenue each year. The medical equipment provider earns $-83,070,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Nevro have?

Nevro employs 843 workers across the globe.

What is Nevro's official website?

The official website for Nevro is www.nevro.com.

Where are Nevro's headquarters?

Nevro is headquartered at 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at [email protected].

This page was last updated on 9/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at con[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.